Clinical Trial Update: Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Ramelteon (Rozerem) for sleep disturbances in Parkinson's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ROZEREM (ramelteon)

Snippet

Sponsor: Southern California Institute for Research and Education | Conditions: Parkinson's Disease | Phase 4 | Status: TERMINATED